Neuren Pharmaceuticals is a biopharmaceutical company developing new drug therapies for serious neurological disorders caused by genetic abnormalities or brain injury. The company's principal activities consist of the development of pharmaceutical products for neurodevelopmental disorders and earning royalty revenue from the licensing of intellectual property. Neuren has granted an exclusive worldwide license to Acadia Pharmaceuticals for the development and commercialization of trofinetide, marketed as DAYBUE and DAYBUE STIX, which is approved in the United States, Canada, and Israel for the treatment of Rett syndrome. The company is also advancing its second drug candidate, NNZ-2591 (ercanetide), an oral solution in clinical development for Phelan-McDermid syndrome, Pitt Hopkins syndrome, Angelman syndrome, and hypoxic ischemic encephalopathy. Neuren targets the role of Insulin-like growth factor 1 (IGF-1) in the brain using orally administered analogs of naturally occurring peptides. Its markets include the United States, Europe, and Japan, with commercialization and regulatory activities focused on these regions. The company holds orphan drug designations in the United States and the European Union for its clinical programs.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Pharmaceuticals, Biotechnology & Life Sciences Homepage neurenpharma.com
Sector Healthcare IR page neurenpharma.com/investor-dashboard
Tags
neurodevelopmental disorders, rare diseases, peptide therapeutics, oral formulations, royalty licensing, clinical trials, genetic disorders, brain injury, trofinetide, DAYBUE, DAYBUE STIX, NNZ-2591, ercanetide, Acadia Pharmaceuticals, Koala
Press page —

Metrics

Valuation  
Market cap A$ 2.999B
Market cap (USD) $ 2.035B
P/E 78.70
PEG 0.18
P/BV 4.69
P/S 33.43
P/OCF 586.18
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 448.9%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue — 84.836M 213.243M 231.925M 14.553M 3.636M 964K 1.016M 15.169M 10.16M 3.338M 3.106M 4.368M 4.978M 4.348M 3.428M 4.907M
Net profit — 30.436M 142.043M 157.081M 184K -7.794M -9.193M -10.816M 3.073M 3.288M -12.014M -13.397M -8.297M -10.436M -4.999M -4.846M -5.122M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 12.34 12.34 — — — — — — — — — — — — — — —
P/OCF — 12.46 — — — — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Zita Peach to succeed Patrick Davies as Board Chair Bull 1 Bear 0 Management

Prompts

Neuren Pharmaceuticals Limited (ticker NEU), listed in Australia.

Company History

Date Change Detail
Dec 31, 2013 Reporting currency Its AU reports are in AUD instead of NZD from this period. Earlier figures are shown in AUD, converted at each period end's exchange rate.

ETFs Holding Neuren Pharmaceuticals Limited

ETF Weight in ETF Shares Market value As of
DFIS 0.05% 165,625 $ 2.669M Nov 12, 2026
DXIV 0.02% 2,302 $ 37.091K Nov 12, 2026
DFSI 0.01% 5,989 $ 96.497K Nov 12, 2026
DFAI 0.01% 58,313 $ 939.565K Nov 12, 2026
DFIC 0.01% 49,145 $ 791.846K Nov 12, 2026
DFAX 0.00% 16,021 $ 258.138K Nov 12, 2026